Family Planning Through Dairy Cooperatives
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This observational study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by Land O'Lakes in Kenya.
| Condition |
|---|
|
The Study Goal is to Assess the Introduction of Sustainable Family Planning/Reproductive Health Information and Services Through Land O' Lakes-supported Dairy Cooperatives |
| Study Type: | Observational |
| Official Title: | Providing Family Planning Services Sustainably Through Dairy Cooperatives in Kenya |
- Health Services Research [ Time Frame: 1 year ] [ Designated as safety issue: No ]Unmet need for family planning among women attending Field Days aged 18-49
- Health Services Research [ Time Frame: 1 year ] [ Designated as safety issue: No ]Interest in receiving health services through Field Day model
| Estimated Enrollment: | 300 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Access to family planning and other reproductive health services remains difficult in much of rural Kenya. One option for improving rural access to family planning is to use existing community events outside of the health sector as platforms for delivering information and services. This study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by Land O'Lakes in Kenya. During these events, known as Field Days, a healthcare provider will have a tent in which Field Day attendees can receive basic family health services free of charge. The services offered will be: family planning counseling and methods, immunizations, antenatal care, screening and treatment for sexually transmitted infections, and HIV counseling and testing. Since the services are no different than those that could be obtained at Ministry of Health or some private facilities, the service provision is not considered to be part of the research.
Women receiving any service from the health care provider will be recruited for an interview that will measure their demand for family planning and attitudes about receiving services during the field day. In addition, the study will track the number of different types of services provided, the total number of Field Day attendees, and the cost of the service model. The study will be carried out at five Field Days in Rift Valley and Central provinces.
Participants will not be tested for STI/HIV as part of this research; however, at their request, they may have received a test from the provider prior to the research interview. At the time of consent, they will have already received the test, so the consent form will not include anything specific to testing. In Kenya, all STI/HIV test results are reported to the national public health authorities. These reports are not used for contacting patients but for planning purposes.
Eligibility| Ages Eligible for Study: | 18 Years to 49 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Females aged 18-49
Inclusion Criteria:females aged 18-49 receiving health services at a field day event -
Exclusion Criteria:
-
Contacts and Locations| Kenya | |
| 5 Community Outreach Events | |
| Various, Rift Valley & Central, Kenya | |
| Principal Investigator: | John Bratt, MPP, MA | FHI 360 |
More Information
No publications provided
| Responsible Party: | John Bratt, FHI |
| ClinicalTrials.gov Identifier: | NCT01226433 History of Changes |
| Other Study ID Numbers: | 10227 |
| Study First Received: | October 8, 2010 |
| Last Updated: | August 9, 2011 |
| Health Authority: | United States: Institutional Review Board Kenya: Kenya Medical Research Institute Ethics Review Board |
Keywords provided by FHI 360:
|
AE adverse event AIDS acquired immunodeficiency syndrome ALT (SGPT) alanine aminotransferase ART antiretroviral therapy AST (SGOT) aspartate aminotransferase DCF data collection forms DMC Data Monitoring Committee FDA (U.S.) Food and Drug Administration GCP Good Clinical Practice guidelines HB sAg Hepatitis B surface antigen ICH International Conference of Harmonisation |
IND Investigational New Drug Application IRB Institutional Review Board IU International units mg milligram(s) mm3 cubic millimeter(s) PCR polymerase chain reaction SAE serious adverse event µg microgram ULN upper limit of the normal range WB Western Blot |
ClinicalTrials.gov processed this record on February 28, 2013
